Connection
Michael Szarek to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Michael Szarek has written about Randomized Controlled Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.290 |
|
|
|
-
Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, Butler J, Cherney DZI, Herrington WG, Inzucchi SE, Jardine MJ, Liu CC, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Sabatine MS, Solomon SD, Staplin N, Szarek M, Vaduganathan M, Wanner C, Wheeler DC, Wiviott SD, Zannad F, Heerspink HJL. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024 08; 12(8):545-557.
Score: 0.129
-
Ismail A, Erne G, Vasbinder A, Hutten CG, Ghazzal BZ, Pizzo I, Diaz KM, Catalan TC, Farhat T, Knott B, Kunkle P, Szarek M, Davies MJ, Steg PG, Pitt B, Bhatt DL, Hayek SS. Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients With Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study. J Card Fail. 2026 Aug; 32(8):1362-1372.
Score: 0.036
-
Nicholls SJ, Nelson AJ, Ray KK, Ballantyne CM, Ditmarsch M, Kling D, Hsieh A, Szarek M, Kastelein JJ, Davidson MH. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
Score: 0.035
-
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. Eur Heart J Cardiovasc Pharmacother. 2024 07 16; 10(4):342-352.
Score: 0.032
-
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J. 2022 04; 246:136-143.
Score: 0.027
-
Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol. 2017 08; 24(12):1294-1296.
Score: 0.020
-
Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008 Jun 10; 117(23):3002-9.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|